FDA Eyes Renewal for 'Safer' Cigarettes—Smokers, Weigh In!
Published Date: 5/13/2026
Notice
Summary
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Renewal Must Meet Section 911(g)(2) Tests
The applicant seeking renewal is pursuing an order under section 911(g)(2) of the FD&C Act and must demonstrate several statutory points, including that the order would promote public health, that claims are limited to reduced exposure or reduced levels of substances, that available scientific evidence reasonably predicts measurable and substantial reductions in morbidity or mortality, and that consumers will not be misled. These statutory demonstrations are required for the renewed modified-risk authorization.
Possible Continued Sale of 'Modified Risk' Cigarettes
The company 22nd Century Group Inc. has applied to renew FDA authorization to market VLN® King and VLN® Menthol King as modified risk tobacco products. These products previously received authorization on December 23, 2021; if the renewals are granted they would remain on the market with modified-risk claims (public comment for the applications opened May 13, 2026).
Public Comment Period and Document Posting Rules
FDA posted redacted application documents for public comment beginning May 13, 2026 and will set a closing date that is at least 120 days after this notice and at least 30 days after final documents are posted; the Agency will announce the final closing date at least 30 days in advance. Comments submitted electronically to regulations.gov will be posted publicly unless submitted as confidential written/paper submissions following FDA instructions.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09268 — Postapproval Pregnancy Safety Studies; Guidance for Industry; Availability
The FDA just released final guidance to help drug makers study how their medicines affect pregnant women after approval. This update affects companies and researchers who must now follow clearer steps to check pregnancy safety, helping protect moms and babies. The guidance is effective immediately, with no new costs announced, but it encourages better, safer studies going forward.
Previous / Next Documents
Previous: 2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
Next: 2026-09545 — Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V REMEDY
The government is asking for your thoughts on letting a foreign-built small passenger boat, the M/V REMEDY, operate in U.S. coastal waters carrying up to 12 passengers. This could affect U.S. boat builders and businesses that use American-made vessels, so they want to make sure it won’t hurt local jobs or trade. You have until June 12, 2026, to share your opinion—no cost changes yet, just a decision in the works!